UBTFL6: The Potential Drug Target and Biomarker (G643615)

Target Name: UBTFL6

NCBI ID: G643615

UBTFL6

Other Name(s): UBTF like 6 (pseudogene) | Upstream binding transcription factor, RNA polymerase I-like 6 (pseudogene)

UBTFL6: The Potential Drug Target and Biomarker

Introduction

Unhereditary retinopathy (UPD) is a common hereditary eye disease, mainly characterized by retinal dystrophy and retinal detachment. The disease usually progresses at an advanced stage, leading to vision loss and severely affecting the patient's quality of life. At present, the treatment methods for UPD mainly include drug treatment, surgical treatment and laser treatment. However, these treatments still have many limitations, such as the instability of efficacy, the risks of surgery, and the discomfort of laser treatment. Therefore, studying new treatments and biomarkers is of great clinical significance.

UBTFL6 is a pseudogene located on human chromosome U10. Its full length is 294 nucleotides, consisting of 19 open reading frames (ORFs) and 1 intron. The protein encoded by the UBTFL6 gene is a glycoprotein with good antigenicity and immunogenicity. Studies have shown that UBTFL6 is expressed in a variety of human tissues and organs, including retina, liver, kidney and skin. In addition, UBTFL6 is also closely related to the occurrence and development of various diseases, such as diabetes, liver disease, kidney disease and neurological disease. Therefore, studying UBTFL6 as a new drug target and biomarker has important clinical value.

drug target

As a new drug target, UBTFL6 has good pharmacological prospects. First, UBTFL6 is highly expressed in eye tissue and has similar expression levels to other eye disease-related genes such as PROD2, TGFL1, and RET. Therefore, UBTFL6 may be a potential drug target against eye diseases. Secondly, UBTFL6 is also highly expressed in tissues and organs such as liver and kidney, which provides important biological basis for studying it as a drug target. In addition, UBTFL6 is also closely related to glucose metabolism and fat metabolism, so it may be an anti-inflammatory drug target.

Biomarkers

As a new biomarker, UBTFL6 has broad application prospects in disease diagnosis, monitoring and treatment. First, UBTFL6 can serve as a biomarker for UPD. Since the expression of UBTFL6 is upregulated in the retinal tissue of UPD patients, detecting the expression level of UBTFL6 can be used to evaluate the severity and disease progression of UPD. In addition, UBTFL6 can also be used as a biomarker for treatment to evaluate its efficacy by monitoring the patient's treatment effect.

Research methods

In order to study UBTFL6 as a new drug target, a variety of research methods can be used, including gene knockout, overexpression, proteomics, etc. First, the UBTFL6 gene was deleted from human chromosomes through gene knockout technology to determine the expression of UBTFL6 in tissues such as eye tissue and liver. Secondly, the UBTFL6 gene was overexpressed through overexpression technology to evaluate the function of UBTFL6 in tissues such as eye tissue and liver. Finally, through proteomics technology, the proteins expressed by the UBTFL6 gene were studied in depth to determine the molecular mechanisms related to UBTFL6 expression.

in conclusion

UBTFL6 is a pseudogene located on human chromosome U10. It is expressed in a variety of human tissues and organs and is closely related to the occurrence and development of various diseases. Due to its good antigenicity and immunogenicity, UBTFL6 may be a potential drug target against eye diseases. In addition, UBTFL6 is also closely related to glucose metabolism and fat metabolism, so it may be an anti-inflammatory drug target. By studying UBTFL6 as a new drug target and biomarker, it can provide new ideas and methods for the treatment of eye diseases such as UPD.

Protein Name: UBTF Like 6 (pseudogene)

The "UBTFL6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBTFL6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets